NuProbe VarMap Panels

Houston-based sample preparation firm NuProbe has launched its VarMap targeted next-generation sequencing product line. NuProbe's first target enrichment assays include multi-gene panels for non-small cell lung cancer and melanoma. They require 500x sequencing depth to detect and quantitate tumor-specific mutations at 0.1 percent variant allele frequency. The assays allow for detection of low-abundance tumor-specific mutations to help with therapy selection and minimal residual disease monitoring, the company said.